Our results also showed in agreement with a recent study52 that the current version of the neurocognitive blood test including P‐tau, GFAP, and NfL is less useful to discriminate AD from DLB, which is in line with expectations due to high prevalence of AD co‐pathology in DLB (in the current dataset: 49%). The gene discussed is MAPT; the disease is Alzheimer disease.